- EN-374 is a gene therapy that works by adding a functioning copy of the CYBB gene directly into the body.
- EN-374 is being developed by Ensoma, a biotechnology company.
Clinical Trial Locations
Multiple clinical trial sites are being opened across the US. If you are interested in learning more or participating, please speak with your physician or reach out to one of the investigators listed below and on clnicaltrials.gov, study identifier
NCT06876363.
Now Open for Enrollment
University of Minnesota
Minneapolis, Minnesota, 55454
Contact:
Alli Travis, BSN, RN, BMTCN
612-625-6150
Principal Investigator:
Christen Ebens, MD, MPH
University of Utah, Primary Children's Hospital
Salt Lake City, Utah
84113
Contact:
Morgan Badgley, BS, CCRC
801-662-4812
Principal Investigator:
Ahmad Rayes, MD, MSc
Columbia University Irving Medical Center, Morgan Stanley Children's Hospital
New York, NY 10034
Contact:
Brianna Mayo, PNP, RN
212-305-2372
Principal Investigator:
Joseph Oved, MD
Duke University
Durham,
North Carolina 27710
Contact:
Linda Brown
919-613-1482
Principal Investigator:
Talal Mousallem, MD
Principal Investigator :
Kris Mahadeo, MD, MPH
Opening Soon:
Additional trial locations opening soon in the US--check back for updates.




